MacroGenics to Participate in Upcoming Investor Conferences
02 mars 2023 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, March 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
Standard Lithium to Participate in the BMO 32nd Global Metals, Mining & Critical Minerals Conference
23 févr. 2023 16h01 HE
|
Standard Lithium
VANCOUVER, British Columbia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE: SLI) (FRA: S5L), a leading near-commercial lithium...
MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 17h50 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics...
MacroGenics to Participate in Upcoming Investor Conferences
02 nov. 2022 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 02, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
INmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the Baird Global Healthcare Conference
07 sept. 2022 09h00 HE
|
INmune Bio, Inc.
Boca Raton, FL, Sept. 07, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical- stage immunology company focused on developing treatments that harness the patient’s immune system to fight...
MacroGenics to Participate in Upcoming Investor Conferences
02 sept. 2022 07h00 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Sept. 02, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics...
MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call
25 juil. 2022 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, July 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer
08 juil. 2022 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, July 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...
MacroGenics to Participate in Upcoming Investor Conference
08 juin 2022 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, June 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
MacroGenics Announces Appointment of William Heiden to Board of Directors
23 mai 2022 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, May 23, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...